CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • Cytomegalovirus Infections
  • Cytosine
  • Hematopoietic Stem Cell Transplantation
  • Organophosphonates

abstract

  • Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced the incidence of CMV events in recipients of hematopoietic-cell transplants. Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly. (Funded by Chimerix; CMX001-201 ClinicalTrials.gov number, NCT00942305.).

publication date

  • September 27, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1303688

PubMed ID

  • 24066743

Additional Document Info

start page

  • 1227

end page

  • 36

volume

  • 369

number

  • 13